Jamie Kurtz

Robins Kaplan LLP

+ Follow Contact

Latest Publications

Share:

Personalized Medicine and Patent Eligibility under 35 U.S.C. § 101

Double-digit growth is predicted for the molecular diagnostic market in the next several years, driven in part by an increased demand for personalized medicine—medical decisions and therapeutic products tailored to address...more

4/25/2014 / Bristol-Myers Squibb , Diagnostic Tests , Food and Drug Administration (FDA) , Genetic Technologies Ltd. , Healthcare , Infringement , Patent Litigation , Patents , Sequenom

1 Results

View per page

Page: of 1

Jamie Kurtz

Robins Kaplan LLP

Popular Topics by This Author

Latest Publications

Personalized Medicine and Patent Eligibility under 35 U.S.C. § 101

"My best business intelligence, in one easy email…"